Clients

Drug Royalty II

$701,420,000

Drug Royalty II

Drug Royalty II was formed to acquire shares in the royalties of drug sales from pharmaceutical and biotechnology companies, research institutions, universities and inventors.   In March 2010, Drug Royalty II achieved an oversubscribed final close with over $701 million of capital commitments.

DRI Capital is a Toronto-based global leader in healthcare investing.  Established in 1992, DRI Capital pioneered royalty monetization as a commonly accepted option for owners of intellectual property. 

Back to Clients